Guardant Health, Inc. stock analysis
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tum
- Ticker
- GH
- Exchange
- Nasdaq
- Sector
- Health Care
- Industry
- Health Care Equipment & Services
What should I review before buying Guardant Health, Inc. stock?
Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.
Inside the full analysis
- Valuation
- Growth
- Financial health
- Ownership
- Research
Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.
Sign in to open the analysis